Take-at-home tests boost colorectal cancer screening 10x for the underserved

February 08, 2021

Colorectal cancer screening rates jumped by more than 1,000 percent when researchers sent take-at-home tests to patients overdue for testing at a community health center that predominantly serves people of color. Instead of the oft-standard text message that simply reminds a patient that they are overdue for screening, researchers from the Perelman School of Medicine at the University of Pennsylvania made it the default to send a take-at-home test to the patient's home unless they opted out via a text message prompt. The research was published in the Journal of General Internal Medicine.

"Colorectal cancer screening rates remain limited in underserved populations, which includes those in the clinic we partnered with," Shivan Mehta, MD, associate chief innovation officer at Penn Medicine and an assistant professor of Medicine. "We saw that there is an opportunity to use text messaging and new insights from behavioral science to increase uptake."

Colorectal cancer can be especially deadly if it is not discovered early enough for curative treatment. Across the United States, regular screening rates are relatively low, particularly in community health centers, where less than half of eligible patients are up-to-date. One study, in particular, found that the number of deaths from colorectal cancer among Black people was 40 percent higher than in white people, and 100 percent higher than in Asian/Pacific Islanders.

One method consistently used to boost screenings is the fecal immunochemical test (FIT). These kits just require a stool sample from a patient -- which can be provided at home -- that are then returned to a laboratory by mail and analyzed for the trace blood associated with colorectal cancer. While a colonoscopy remains the gold standard because it is the most thorough check and only needs to be completed once every 10 years, FIT kits are much easier for patients to handle and likely to be completed, even though they only clear a patient for a year.

Looking to increase low completion rates, the researchers -- led by Mehta and the study's first author, Sarah Huf, MBBS, a former Commonwealth Fund Fellow at Penn and now an Honorary Clinical Lecturer at Imperial College London -- decided to focus on completing FIT kits. As such, they randomly split a group of more than 400 patients overdue for screenings into two equal arms: one that just received a single reminder text and another that received FIT kits unless patients sent a response to an introduction text to say that they didn't want them. Almost 90 percent of these patients were Black, and half were Medicaid beneficiaries.

From March to May 2018, these patients were enrolled to either receive the reminder text (the control group) or to receive the FIT kit pending an opt-out (the intervention group). The latter group also received up to three follow-up texts with messages based on proven behavioral science techniques to nudge them into returning the kits.

By the end of the period studied (12 weeks from when each patient received their first text message) a little more than 2 percent of the patients in the control group had completed a FIT kit or had a colonoscopy. But for the intervention arm of the study, nearly 20 percent had done the same.

When looking purely at FIT kit return rates, the intervention arm increased by more than 17 percentage points. In the control, it was less than two. And while screening rates did remain relatively low, the improvement showed great promise for the population served.

"It is important to note that this is a population at a community health center that may not routinely seek out medical care, especially preventive care, so there is a low baseline screening rate," Huf explained. "Future interventions may need to address issues such as reading comprehension and not having a stable place to live."

What was especially important for the type of clinic this study was performed in was the cost to apply it. For the 200 patients in the intervention arm, it only cost about $150.

"For these types of health clinics, minimizing cost is critical for sustainability since they have many competing health priorities for their patients," Mehta said.

Moving forward, Mehta and his fellow researchers plan to explore how best to offer the choice of colonoscopy or FIT kits to patients in the populations that receive care at this type of health center.
-end-
This study was funded partly by a grant from the National Cancer Center (K08CA234326).

Other co-authors on the study included David A. Asch, Kevin G. Volpp, and Catherine Reitz.

University of Pennsylvania School of Medicine

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.